• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022

    5/23/22 10:33:41 AM ET
    $ABBV
    $ABG
    $ADSK
    $AMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary
    Get the next $ABBV alert in real time by email

     

    Upgrades

    • According to Morgan Stanley, the prior rating for Motorola Solutions Inc (NYSE:MSI) was changed from Equal-Weight to Overweight. Motorola Solns earned $1.70 in the first quarter, compared to $1.87 in the year-ago quarter. At the moment, the stock has a 52-week-high of $273.65 and a 52-week-low of $198.61. Motorola Solns closed at $210.28 at the end of the last trading period.
    • According to Morgan Stanley, the prior rating for Zebra Technologies Corp (NASDAQ:ZBRA) was changed from Underweight to Equal-Weight. For the first quarter, Zebra Technologies had an EPS of $4.01, compared to year-ago quarter EPS of $4.79. At the moment, the stock has a 52-week-high of $615.00 and a 52-week-low of $309.00. Zebra Technologies closed at $325.37 at the end of the last trading period.
    • Morgan Stanley upgraded the previous rating for Trimble Inc (NASDAQ:TRMB) from Underweight to Equal-Weight. For the first quarter, Trimble had an EPS of $0.73, compared to year-ago quarter EPS of $0.66. At the moment, the stock has a 52-week-high of $96.49 and a 52-week-low of $59.89. Trimble closed at $65.23 at the end of the last trading period.
    • Truist Securities upgraded the previous rating for Treehouse Foods Inc (NYSE:THS) from Hold to Buy. For the first quarter, Treehouse Foods had an EPS of $0.15, compared to year-ago quarter EPS of $0.36. At the moment, the stock has a 52-week-high of $51.49 and a 52-week-low of $29.47. Treehouse Foods closed at $36.70 at the end of the last trading period.
    • According to Credit Suisse, the prior rating for DTE Energy Co (NYSE:DTE) was changed from Neutral to Outperform. In the first quarter, DTE Energy showed an EPS of $2.31, compared to $2.44 from the year-ago quarter. The current stock performance of DTE Energy shows a 52-week-high of $142.88 and a 52-week-low of $108.22. Moreover, at the end of the last trading period, the closing price was at $128.72.
    • Guggenheim upgraded the previous rating for Consolidated Edison Inc (NYSE:ED) from Sell to Neutral. In the first quarter, Consolidated Edison showed an EPS of $1.47, compared to $1.44 from the year-ago quarter. The stock has a 52-week-high of $99.22 and a 52-week-low of $71.17. At the end of the last trading period, Consolidated Edison closed at $95.81.
    • For CubeSmart (NYSE:CUBE), Raymond James upgraded the previous rating of Outperform to Strong Buy. CubeSmart earned $0.58 in the first quarter, compared to $0.47 in the year-ago quarter. The current stock performance of CubeSmart shows a 52-week-high of $57.34 and a 52-week-low of $40.31. Moreover, at the end of the last trading period, the closing price was at $40.84.
    • According to UBS, the prior rating for Saia Inc (NASDAQ:SAIA) was changed from Neutral to Buy. In the first quarter, Saia showed an EPS of $2.98, compared to $1.40 from the year-ago quarter. The current stock performance of Saia shows a 52-week-high of $365.50 and a 52-week-low of $173.64. Moreover, at the end of the last trading period, the closing price was at $187.55.

    See all analyst ratings upgrades.

     

    Downgrades

    • According to KGI Securities, the prior rating for Nike Inc (NYSE:NKE) was changed from Outperform to Neutral. Nike earned $0.87 in the third quarter, compared to $0.90 in the year-ago quarter. At the moment, the stock has a 52-week-high of $179.10 and a 52-week-low of $105.00. Nike closed at $108.00 at the end of the last trading period.
    • For HP Inc (NYSE:HPQ), Citigroup downgraded the previous rating of Buy to Neutral. In the first quarter, HP showed an EPS of $1.10, compared to $0.92 from the year-ago quarter. The current stock performance of HP shows a 52-week-high of $41.47 and a 52-week-low of $26.11. Moreover, at the end of the last trading period, the closing price was at $34.65.
    • According to Morgan Stanley, the prior rating for Group 1 Automotive Inc (NYSE:GPI) was changed from Equal-Weight to Underweight. In the first quarter, Group 1 Automotive showed an EPS of $10.81, compared to $5.57 from the year-ago quarter. At the moment, the stock has a 52-week-high of $212.23 and a 52-week-low of $143.00. Group 1 Automotive closed at $173.76 at the end of the last trading period.
    • According to Morgan Stanley, the prior rating for Asbury Automotive Group Inc (NYSE:ABG) was changed from Equal-Weight to Underweight. In the first quarter, Asbury Automotive Group showed an EPS of $9.27, compared to $4.68 from the year-ago quarter. At the moment, the stock has a 52-week-high of $230.97 and a 52-week-low of $146.43. Asbury Automotive Group closed at $170.96 at the end of the last trading period.
    • According to Citigroup, the prior rating for Corning Inc (NYSE:GLW) was changed from Buy to Neutral. In the first quarter, Corning showed an EPS of $0.54, compared to $0.45 from the year-ago quarter. At the moment, the stock has a 52-week-high of $44.30 and a 52-week-low of $32.23. Corning closed at $33.13 at the end of the last trading period.
    • According to Wolfe Research, the prior rating for JBG SMITH Properties (NYSE:JBGS) was changed from Outperform to Peer Perform. In the first quarter, JBG SMITH Properties showed an EPS of $0.34, compared to $0.38 from the year-ago quarter. The stock has a 52-week-high of $34.98 and a 52-week-low of $23.54. At the end of the last trading period, JBG SMITH Properties closed at $24.97.
    • Raymond James downgraded the previous rating for Covetrus Inc (NASDAQ:CVET) from Outperform to Market Perform. Covetrus earned $0.25 in the first quarter, compared to $0.21 in the year-ago quarter. The stock has a 52-week-high of $29.02 and a 52-week-low of $13.39. At the end of the last trading period, Covetrus closed at $19.71.
    • Deutsche Bank downgraded the previous rating for Autodesk Inc (NASDAQ:ADSK) from Buy to Hold. In the fourth quarter, Autodesk showed an EPS of $1.50, compared to $1.18 from the year-ago quarter. At the moment, the stock has a 52-week-high of $344.39 and a 52-week-low of $175.41. Autodesk closed at $191.41 at the end of the last trading period.
    • Citigroup downgraded the previous rating for Skillz Inc (NYSE:SKLZ) from Buy to Neutral. In the first quarter, Skillz showed an EPS of $0.21, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $24.88 and a 52-week-low of $1.39. Skillz closed at $1.83 at the end of the last trading period.
    • B of A Securities downgraded the previous rating for Athersys Inc (NASDAQ:ATHX) from Neutral to Underperform. For the first quarter, Athersys had an EPS of $0.09, compared to year-ago quarter EPS of $0.13. The stock has a 52-week-high of $1.81 and a 52-week-low of $0.25. At the end of the last trading period, Athersys closed at $0.26.
    • According to Piper Sandler, the prior rating for Dow Inc (NYSE:DOW) was changed from Overweight to Neutral. For the first quarter, Dow had an EPS of $2.34, compared to year-ago quarter EPS of $1.36. The current stock performance of Dow shows a 52-week-high of $71.86 and a 52-week-low of $52.07. Moreover, at the end of the last trading period, the closing price was at $68.11.

    See all analyst ratings downgrades.

     

    Initiations

    • With an Outperform rating, KGI Securities initiated coverage on The Walt Disney Co (NYSE:DIS). The price target seems to have been set at $145.00 for Walt Disney. For the second quarter, Walt Disney had an EPS of $1.08, compared to year-ago quarter EPS of $0.79. The stock has a 52-week-high of $187.58 and a 52-week-low of $99.47. At the end of the last trading period, Walt Disney closed at $102.42.
    • With a Buy rating, Maxim Group initiated coverage on Charge Enterprises Inc (NASDAQ:CRGE). The price target seems to have been set at $8.00 for Charge Enterprises. At the moment, the stock has a 52-week-high of $8.46 and a 52-week-low of $2.51. Charge Enterprises closed at $3.70 at the end of the last trading period.
    • With an Outperform rating, Northland Capital Markets initiated coverage on Array Technologies Inc (NASDAQ:ARRY). The price target seems to have been set at $18.00 for Array Technologies. For the first quarter, Array Technologies had an EPS of $0.02, compared to year-ago quarter EPS of $0.19. The stock has a 52-week-high of $27.67 and a 52-week-low of $5.45. At the end of the last trading period, Array Technologies closed at $9.07.
    • Craig-Hallum initiated coverage on Applied Blockchain Inc (NASDAQ:APLD) with a Buy rating. The price target for Applied Blockchain is set to $10.00. In the third quarter, Applied Blockchain showed an EPS of $0.12, compared to $0.05 from the year-ago quarter. The stock has a 52-week-high of $5.70 and a 52-week-low of $0.61. At the end of the last trading period, Applied Blockchain closed at $3.65.
    • FBN Securities initiated coverage on Alteryx Inc (NYSE:AYX) with an Outperform rating. The price target for Alteryx is set to $80.00. For the first quarter, Alteryx had an EPS of $0.40, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $90.57 and a 52-week-low of $49.67. At the end of the last trading period, Alteryx closed at $55.66.
    • Cowen & Co. initiated coverage on The Hain Celestial Group Inc (NASDAQ:HAIN) with an Outperform rating. The price target for Hain Celestial Group is set to $34.00. Hain Celestial Group earned $0.33 in the third quarter, compared to $0.44 in the year-ago quarter. The current stock performance of Hain Celestial Group shows a 52-week-high of $48.88 and a 52-week-low of $24.11. Moreover, at the end of the last trading period, the closing price was at $24.77.
    • With a Market Perform rating, Cowen & Co. initiated coverage on Lancaster Colony Corp (NASDAQ:LANC). The price target seems to have been set at $140.00 for Lancaster Colony. In the third quarter, Lancaster Colony showed an EPS of $0.71, compared to $1.05 from the year-ago quarter. The current stock performance of Lancaster Colony shows a 52-week-high of $201.31 and a 52-week-low of $118.99. Moreover, at the end of the last trading period, the closing price was at $121.72.
    • Atlantic Equities initiated coverage on Westinghouse Air Brake Technologies Corp (NYSE:WAB) with an Overweight rating. The price target for Westinghouse Air Brake is set to $101.00. In the first quarter, Westinghouse Air Brake showed an EPS of $1.13, compared to $0.89 from the year-ago quarter. At the moment, the stock has a 52-week-high of $100.05 and a 52-week-low of $76.30. Westinghouse Air Brake closed at $86.96 at the end of the last trading period.
    • Cowen & Co. initiated coverage on Piedmont Lithium Inc (NASDAQ:PLL) with an Outperform rating. The price target for Piedmont Lithium is set to $90.00. The stock has a 52-week-high of $79.99 and a 52-week-low of $40.65. At the end of the last trading period, Piedmont Lithium closed at $58.01.
    • With an Outperform rating, SVB Leerink initiated coverage on Theravance Biopharma Inc (NASDAQ:TBPH). The price target seems to have been set at $12.00 for Theravance Biopharma. In the first quarter, Theravance Biopharma showed an EPS of $0.22, compared to $1.24 from the year-ago quarter. The current stock performance of Theravance Biopharma shows a 52-week-high of $18.83 and a 52-week-low of $6.10. Moreover, at the end of the last trading period, the closing price was at $8.74.
    • SVB Leerink initiated coverage on Eli Lilly and Co (NYSE:LLY) with an Outperform rating. The price target for Eli Lilly is set to $341.00. For the first quarter, Eli Lilly had an EPS of $2.62, compared to year-ago quarter EPS of $1.87. The stock has a 52-week-high of $314.00 and a 52-week-low of $195.50. At the end of the last trading period, Eli Lilly closed at $298.85.
    • With a Market Perform rating, SVB Leerink initiated coverage on Horizon Therapeutics PLC (NASDAQ:HZNP). The price target seems to have been set at $95.00 for Horizon Therapeutics. For the first quarter, Horizon Therapeutics had an EPS of $1.34, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $120.53 and a 52-week-low of $82.51. Horizon Therapeutics closed at $90.35 at the end of the last trading period.
    • With a Market Perform rating, SVB Leerink initiated coverage on Radius Health Inc (NASDAQ:RDUS). The price target seems to have been set at $7.00 for Radius Health. Radius Health earned $0.39 in the first quarter, compared to $0.18 in the year-ago quarter. The current stock performance of Radius Health shows a 52-week-high of $23.00 and a 52-week-low of $4.97. Moreover, at the end of the last trading period, the closing price was at $6.25.
    • JP Morgan initiated coverage on Porch Group Inc (NASDAQ:PRCH) with an Overweight rating. The price target for Porch Group is set to $8.00. Porch Group earned $0.06 in the first quarter, compared to $0.76 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.50 and a 52-week-low of $3.27. Porch Group closed at $4.45 at the end of the last trading period.
    • With a Sector Perform rating, RBC Capital initiated coverage on Upwork Inc (NASDAQ:UPWK). The price target seems to have been set at $21.00 for Upwork. Upwork earned $0.03 in the first quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $64.49 and a 52-week-low of $14.85. At the end of the last trading period, Upwork closed at $18.33.
    • With a Market Perform rating, SVB Leerink initiated coverage on Amgen Inc (NASDAQ:AMGN). The price target seems to have been set at $256.00 for Amgen. In the first quarter, Amgen showed an EPS of $4.25, compared to $3.70 from the year-ago quarter. The stock has a 52-week-high of $258.45 and a 52-week-low of $198.64. At the end of the last trading period, Amgen closed at $247.50.
    • SVB Leerink initiated coverage on AbbVie Inc (NYSE:ABBV) with an Underperform rating. The price target for AbbVie is set to $140.00. For the first quarter, AbbVie had an EPS of $3.16, compared to year-ago quarter EPS of $2.95. The current stock performance of AbbVie shows a 52-week-high of $175.91 and a 52-week-low of $105.56. Moreover, at the end of the last trading period, the closing price was at $151.01.
    • SVB Leerink initiated coverage on Gilead Sciences Inc (NASDAQ:GILD) with a Market Perform rating. The price target for Gilead Sciences is set to $68.00. In the first quarter, Gilead Sciences showed an EPS of $2.12, compared to $2.08 from the year-ago quarter. At the moment, the stock has a 52-week-high of $74.12 and a 52-week-low of $57.19. Gilead Sciences closed at $63.84 at the end of the last trading period.
    • SVB Leerink initiated coverage on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with an Outperform rating. The price target for Regeneron Pharmaceuticals is set to $738.00. In the first quarter, Regeneron Pharmaceuticals showed an EPS of $11.49, compared to $9.89 from the year-ago quarter. At the moment, the stock has a 52-week-high of $747.42 and a 52-week-low of $492.13. Regeneron Pharmaceuticals closed at $661.14 at the end of the last trading period.
    • SVB Leerink initiated coverage on Vertex Pharmaceuticals Inc (NASDAQ:VRTX) with a Market Perform rating. The price target for Vertex Pharmaceuticals is set to $265.00. For the first quarter, Vertex Pharmaceuticals had an EPS of $3.52, compared to year-ago quarter EPS of $2.98. The stock has a 52-week-high of $292.75 and a 52-week-low of $176.36. At the end of the last trading period, Vertex Pharmaceuticals closed at $258.59.
    • SVB Leerink initiated coverage on Roivant Sciences Ltd (NASDAQ:ROIV) with an Outperform rating. The price target for Roivant Sciences is set to $6.00. The current stock performance of Roivant Sciences shows a 52-week-high of $16.76 and a 52-week-low of $2.52. Moreover, at the end of the last trading period, the closing price was at $3.70.

    See all analyst ratings initiations.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $ABG
    $ADSK
    $AMGN

    CompanyDatePrice TargetRatingAnalyst
    Saia Inc.
    $SAIA
    2/11/2026$425.00Positive → Neutral
    Susquehanna
    Porch Group Inc.
    $PRCH
    2/11/2026$10.50Mkt Perform → Outperform
    Keefe Bruyette
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    Saia Inc.
    $SAIA
    2/10/2026$250.00Equal-Weight → Underweight
    Morgan Stanley
    HP Inc.
    $HPQ
    2/3/2026$20.00Neutral → Underperform
    BofA Securities
    Walt Disney Company
    $DIS
    2/3/2026$135.00Overweight
    Morgan Stanley
    Autodesk Inc.
    $ADSK
    2/2/2026$319.00Neutral → Overweight
    Analyst
    Realty Income Corporation
    $O
    1/30/2026$67.00Sector Perform → Sector Outperform
    Scotiabank
    More analyst ratings

    $ABBV
    $ABG
    $ADSK
    $AMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. VP, Financial Svcs/Mfr Rel Delongchamps Peter C was granted 3,121 shares, increasing direct ownership by 12% to 29,405 units (SEC Form 4)

    4 - GROUP 1 AUTOMOTIVE INC (0001031203) (Issuer)

    2/12/26 7:50:36 PM ET
    $GPI
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    SVP & CFO Mchenry Daniel James was granted 5,183 shares, increasing direct ownership by 40% to 18,281 units (SEC Form 4)

    4 - GROUP 1 AUTOMOTIVE INC (0001031203) (Issuer)

    2/12/26 7:43:25 PM ET
    $GPI
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    New insider Cain Wettan Keeley M claimed ownership of 3,944 shares (SEC Form 3)

    3 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    2/12/26 7:26:43 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dow declares quarterly dividend of 35 cents per share

    MIDLAND, Mich., Feb. 12, 2026 /PRNewswire/ -- Dow (NYSE:DOW) has declared a dividend of 35 cents per share, payable March 13, 2026, to shareholders of record on February 27, 2026. This marks the 458th consecutive dividend paid by the Company or its affiliates since 1912. About DowDow (NYSE:DOW) is one of the world's leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, customer-focused innovation and leading business positions enable u

    2/12/26 4:15:00 PM ET
    $DOW
    Major Chemicals
    Industrials

    Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

    — Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue — — Broad mid- and late-stage clinical pipeline accelerates with multiple proof-of-concept and pivotal programs advancing; on track to complete BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the f

    2/12/26 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolv Technology Announces the Appointment of Henrik Kühl as a New Independent Director

    – Long-Time Member of the Board of Directors and Early Venture Capitalist Bilal Zuberi Resigns from Board – Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced the appointment of Mr. Henrik Kühl, age 46, to its Board of Directors ("Board") effective February 12, 2026. Kühl will also serve on the Board's Audit Committee. The Board affirmatively determined that Kühl is independent and an audit committee financial expert as that term is defined by applicable Securities and Exchange Commission regulations. Kühl is an accomplished leader with over 25 years of experience in c

    2/12/26 8:00:00 AM ET
    $AXON
    $EVLV
    Ordnance And Accessories
    Industrials
    Computer peripheral equipment
    Technology

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Swan Robert Holmes bought $500,080 worth of Class B Common Stock (8,691 units at $57.54), increasing direct ownership by 25% to 43,293 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:21:15 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Saia downgraded by Susquehanna with a new price target

    Susquehanna downgraded Saia from Positive to Neutral and set a new price target of $425.00

    2/11/26 7:50:53 AM ET
    $SAIA
    Trucking Freight/Courier Services
    Industrials

    Porch Group upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded Porch Group from Mkt Perform to Outperform and set a new price target of $10.50

    2/11/26 7:42:24 AM ET
    $PRCH
    Computer Software: Prepackaged Software
    Technology

    Needham reiterated coverage on Gilead Sciences with a new price target

    Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously

    2/11/26 7:05:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $ABG
    $ADSK
    $AMGN
    SEC Filings

    View All

    SEC Form 10-K filed by Corning Incorporated

    10-K - CORNING INC /NY (0000024741) (Filer)

    2/12/26 4:41:48 PM ET
    $GLW
    Telecommunications Equipment
    Industrials

    SEC Form 13F-HR filed by Gilead Sciences Inc.

    13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)

    2/12/26 4:36:53 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Motorola Solutions Inc.

    10-K - Motorola Solutions, Inc. (0000068505) (Filer)

    2/12/26 4:32:07 PM ET
    $MSI
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Skillz Inc.

    SC 13D/A - Skillz Inc. (0001801661) (Subject)

    12/12/24 4:01:36 PM ET
    $SKLZ
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Upwork Inc.

    SC 13G/A - UPWORK, INC (0001627475) (Subject)

    12/9/24 6:02:26 AM ET
    $UPWK
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Corning Incorporated

    SC 13G/A - CORNING INC /NY (0000024741) (Subject)

    11/22/24 6:06:27 AM ET
    $GLW
    Telecommunications Equipment
    Industrials

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evolv Technology Announces the Appointment of Henrik Kühl as a New Independent Director

    – Long-Time Member of the Board of Directors and Early Venture Capitalist Bilal Zuberi Resigns from Board – Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced the appointment of Mr. Henrik Kühl, age 46, to its Board of Directors ("Board") effective February 12, 2026. Kühl will also serve on the Board's Audit Committee. The Board affirmatively determined that Kühl is independent and an audit committee financial expert as that term is defined by applicable Securities and Exchange Commission regulations. Kühl is an accomplished leader with over 25 years of experience in c

    2/12/26 8:00:00 AM ET
    $AXON
    $EVLV
    Ordnance And Accessories
    Industrials
    Computer peripheral equipment
    Technology

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merchants Bancorp Set to Join S&P SmallCap 600

    NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Merchants Bancorp (NASD: MBIN) will replace TreeHouse Foods Inc. (NYSE:THS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 11. Investindustrial S.A. and its affiliates are acquiring Treehouse Foods in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Feb 11, 2026 S&P SmallCap 600 Addition Merchants Bancorp MBIN Financial Feb 11, 2026 S&P SmallCap 600 Deletion TreeHouse Foods THS Consumer Staples ABOUT S&P DOW

    2/6/26 6:24:00 PM ET
    $MBIN
    $SPGI
    $THS
    Major Banks
    Finance
    Finance: Consumer Services
    Packaged Foods

    $ABBV
    $ABG
    $ADSK
    $AMGN
    Financials

    Live finance-specific insights

    View All

    Dow declares quarterly dividend of 35 cents per share

    MIDLAND, Mich., Feb. 12, 2026 /PRNewswire/ -- Dow (NYSE:DOW) has declared a dividend of 35 cents per share, payable March 13, 2026, to shareholders of record on February 27, 2026. This marks the 458th consecutive dividend paid by the Company or its affiliates since 1912. About DowDow (NYSE:DOW) is one of the world's leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, customer-focused innovation and leading business positions enable u

    2/12/26 4:15:00 PM ET
    $DOW
    Major Chemicals
    Industrials

    Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

    — Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue — — Broad mid- and late-stage clinical pipeline accelerates with multiple proof-of-concept and pivotal programs advancing; on track to complete BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the f

    2/12/26 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zebra Technologies Announces Fourth-Quarter and Full-Year 2025 Results

    Fourth-Quarter Financial Highlights Net sales of $1,475 million; year-over-year increase of 10.6% $76 million exit and restructuring charges for actions to increase focus and productivity Net income of $70 million and net income per diluted share of $1.39, year-over-year decrease of 57.1% and 55.7%, respectively Non-GAAP diluted EPS increased 8.3% year-over-year to $4.33 Adjusted EBITDA increased 10.5% year-over-year to $326 million $303 million of share repurchases towards its previously announced $500 million 12-month commitment Zebra Technologies Corporation (NASDAQ:ZBRA), a global leader in digitizing and automating workflows to deliver intelligent operations, today

    2/12/26 6:30:00 AM ET
    $ZBRA
    Industrial Machinery/Components
    Industrials